{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:38:08Z","timestamp":1792147088000,"version":"4.4.0"},"reference-count":14,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Royal College of Physicians of Edinburgh"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:p>We describe a case of a delayed diagnosis of Sezary syndrome in a patient with longstanding generalised pruritus, erythroderma, alopecia and nail dystrophy. We highlight some of the difficulties in diagnosis despite the fact that all patients have a characteristic circulating malignant T-cell lymphocyte in peripheral blood. These cells with cerebriform nuclei should be sought in peripheral blood films and further evaluated using flow cytometry in all patients with an erythrodermatous presentation. We summarise current treatment options although, as with all rare diseases, there are few randomised controlled clinical trials to inform decisions on optimal therapy for each individual patient.<\/jats:p>","DOI":"10.4997\/jrcpe.2012.408","type":"journal-article","created":{"date-parts":[[2012,12,14]],"date-time":"2012-12-14T05:24:23Z","timestamp":1355462663000},"page":"317-321","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Sezary syndrome: diagnosis and management"],"prefix":"10.1177","volume":"42","author":[{"given":"C","family":"Ogilvie","sequence":"first","affiliation":[{"name":"Specialty Trainee, Department of Haematology, Beatson West of Scotland Cancer Centre, Glasgow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Jackson","sequence":"additional","affiliation":[{"name":"Consultant Pathologist, Department of Pathology, Glasgow Royal Infirmary, Glasgow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Leach","sequence":"additional","affiliation":[{"name":"Consultant Haematologist, Department of Haematology, Beatson West of Scotland Cancer Centre, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"McKay","sequence":"additional","affiliation":[{"name":"Consultant Haematologist, Department of Haematology, Beatson West of Scotland Cancer Centre, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2012,12,1]]},"reference":[{"key":"bibr1-JRCPE.2012.408","unstructured":"1 Campo E, Swerdlow SH, Harris NL  WHO classification of tumours of haematopoietic and lymphoid tissues. [Internet] Geneva: World Health Organization; 2008 [cited 2012 Nov 21]. Available from: http:\/\/apps.who.int\/bookorders\/anglais\/detart1.jsp?codlan=1&codcol=70&codcch=4002"},{"key":"bibr2-JRCPE.2012.408","doi-asserted-by":"crossref","unstructured":"2 Trautinger F, Knobler R, Willemze R  EORTC consensus recommendations for the treatment of mycosis fungoides\/Sezary syndrome. Eur J Cancer 2006; 42:1014\u201330. http:\/\/dx.doi.org\/10.1016\/j.ejca.2006.01.025","DOI":"10.1016\/j.ejca.2006.01.025"},{"key":"bibr3-JRCPE.2012.408","doi-asserted-by":"crossref","unstructured":"3 Scarisbrick JJ, Taylor P, Holtick U  UK consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft versus host disease. Br J Dermatol 2008; 158:659\u201378. http:\/\/dx.doi.org\/10.1111\/j.1365-2133.2007.08415.x","DOI":"10.1111\/j.1365-2133.2007.08415.x"},{"key":"bibr4-JRCPE.2012.408","first-page":"1000","volume":"10","author":"Winkelmann RK","year":"1984","journal-title":"The treatment of Sezary syndrome"},{"key":"bibr5-JRCPE.2012.408","doi-asserted-by":"crossref","unstructured":"5 Olsen EA, Rosen ST, Vollmer RT  Interferon alfa-2a in the treatment of cutaneous T cell lymphoma. J Am Acad Dermatol 1989; 20:395\u2013407. http:\/\/dx.doi.org\/10.1016\/S0190-9622(89)70049-9","DOI":"10.1016\/S0190-9622(89)70049-9"},{"key":"bibr6-JRCPE.2012.408","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.376"},{"key":"bibr7-JRCPE.2012.408","first-page":"757","volume":"21","author":"Zackheim HS","year":"1989","journal-title":"Low-dose methotrexate for the Sezary syndrome"},{"key":"bibr8-JRCPE.2012.408","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.9.2456"},{"key":"bibr9-JRCPE.2012.408","doi-asserted-by":"crossref","unstructured":"9 Kennedy GA, Seymour JF, Wolf M  Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab. Eur J Haematol 2003; 71:250\u20136. http:\/\/dx.doi.org\/10.1034\/j.1600-0609.2003.00143.x","DOI":"10.1034\/j.1600-0609.2003.00143.x"},{"key":"bibr10-JRCPE.2012.408","doi-asserted-by":"crossref","unstructured":"10 Akpek G, Koh HK, Bogen S  Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide and oral prednisolone in patients with refractory cutaneous T-cell lymphoma. Cancer 1999; 86:1368\u201376. http:\/\/dx.doi.org\/10.1002\/(SICI)1097-0142(19991001)86:7<1368:AID-CNCR37>3.0.CO;2-8","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1368::AID-CNCR37>3.3.CO;2-#"},{"key":"bibr11-JRCPE.2012.408","doi-asserted-by":"crossref","unstructured":"11 Scarisbrick JJ, Child FJ, Clift A  A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma. Br J Dermatol 2001; 144:1010\u20135. http:\/\/dx.doi.org\/10.1046\/j.1365-2133.2001.04191.x","DOI":"10.1046\/j.1365-2133.2001.04191.x"},{"key":"bibr12-JRCPE.2012.408","doi-asserted-by":"crossref","unstructured":"12 Tirelli U, Carbone A, Zagonel V  Staging and treatment with cyclophosphamide, vincristine and prednisolone (CVP) in advanced cutaneous T-cell lymphomas. Hematol Oncol 1986; 4:83\u201390. http:\/\/dx.doi.org\/10.1002\/hon.2900040110","DOI":"10.1002\/hon.2900040110"},{"key":"bibr13-JRCPE.2012.408","doi-asserted-by":"crossref","unstructured":"13 Duarte RF, Canals C, Onida F  Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010; 28:4492\u20139. http:\/\/dx.doi.org\/10.1200\/JCO.2010.29.3241","DOI":"10.1200\/JCO.2010.29.3241"},{"key":"bibr14-JRCPE.2012.408","doi-asserted-by":"crossref","unstructured":"14 Jones D, Dang NH, Duvic M  Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. Am J Clin Pathol 2001; 115:885\u201392. http:\/\/dx.doi.org\/10.1309\/U1Y6-J4AG-5M4M-7AYV","DOI":"10.1309\/U1Y6-J4AG-5M4M-7AYV"}],"container-title":["Journal of the Royal College of Physicians of Edinburgh"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.4997\/JRCPE.2012.408","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.4997\/JRCPE.2012.408","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:25:58Z","timestamp":1777616758000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.4997\/JRCPE.2012.408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["10.4997\/JRCPE.2012.408"],"URL":"https:\/\/doi.org\/10.4997\/jrcpe.2012.408","relation":{},"ISSN":["1478-2715","2042-8189"],"issn-type":[{"value":"1478-2715","type":"print"},{"value":"2042-8189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}